Addex Achieves Second Milestone In Parkinson’ Disease

Addex, in an exclusive collaboration and license agreement with Merck & Co., has achieved the second preclinical milestone. The collaboration is focused on developing an emerging type of drugs, called allosteric modulators, for treatment of Parkinson’s disease and other undisclosed indications.

The collaboration with Merck emphasises on developing drugs that activate the metabotropic glutamate receptor 4 (mGluR4). The preclinical study showed the desired non-dopaminergic activity profile after oral administration of mGluR4 positive allosteric modulator (PAM) in an animal model of Parkinson’s disease.

Emmanuel Le Poul, Head of CNS Business Unit at Addex, said: “We are pleased that these preclinical data show such promise in the animal model used. This work is a further validation of the target and the strength of our collaboration, as both teams have contributed to this achievement.”